Athira Pharma, Inc. (NASDAQ:LONA) Stock Now Rated “Moderate Buy” by Wall Street Analysts

Shares of Athira Pharma, Inc. (NASDAQ:LONA) have received a consensus recommendation of “Moderate Buy” from the six research firms that are currently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and four have given a buy recommendation to the company. The average 12-month price target among brokers that have issued ratings on the stock in the last year is $17.33.

Several brokerages have commented on LONA. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Athira Pharma in a research report on Friday, August 7th. Mizuho reduced their price objective on Athira Pharma from $16.00 to $15.00 and set an “outperform” rating for the company in a research report on Wednesday, August 19th. Finally, Citizens Jmp lowered their price objective on shares of Athira Pharma from $18.00 to $17.00 and set a “market outperform” rating on the stock in a research note on Monday, August 17th.

Athira Pharma Price Performance

LONA stock opened at $4.82 on Tuesday. Athira Pharma has a 52-week low of $2.21 and a 52-week high of $14.21. The company has a 50-day moving average of $6.94 and a two-hundred day moving average of $8.39. The stock has a market capitalization of $45.26 million, a price-to-earnings ratio of -1.14 and a beta of 2.11.

Athira Pharma (NASDAQ:LONA) last posted its quarterly earnings data on Friday, August 14th. The company reported ($0.80) EPS for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.20). Equities analysts expect that Athira Pharma will post -2.67 EPS for the current fiscal year.

Institutional Trading of Athira Pharma

Several hedge funds and other institutional investors have recently bought and sold shares of LONA. Seven Fleet Capital Management LP acquired a new stake in shares of Athira Pharma during the 4th quarter valued at about $969,000. Commodore Capital LP bought a new stake in Athira Pharma in the fourth quarter valued at about $3,515,000. Finally, Spruce Street Capital LP acquired a new position in Athira Pharma in the fourth quarter worth about $2,980,000. 57.12% of the stock is currently owned by institutional investors and hedge funds.

About Athira Pharma

Athira Pharma, Inc is a biotechnology company focused on developing regenerative medicines for diseases involving neurodegeneration and neurological decline. The company’s research is based on the hepatocyte growth factor (HGF) pathway, which it believes may support neuronal health, repair, and regeneration.

Athira’s lead investigational product is fosgonimeton (also known as ATH-1017), a small-molecule therapy designed to activate the HGF/MET system. The treatment has been studied for Alzheimer’s disease and other neurological conditions, although it remains investigational and has not been approved for commercial use.

Athira was founded in 2011 and is based in the United States.